Look Towards A New Future

Aug 11, 2010

Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy now available at ReportsandReports

Dallas, TX: ReportsandReports announce it will carry Stakeholder Opinions: Ovarian Cancer – Approaching the era of molecular targeted therapy Market Research Report in its Store.

Browse complete Stakeholder Opinions: Ovarian Cancer – Approaching the era of molecular targeted therapy Report

Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ovarian cancer. The high level of unmet need, coupled with the large size of the patient population, is driving extensive R&D interest in this indication. The anticipated incorporation of molecular targeted therapies into treatment is expected to improve patient outcomes in the future.


  • Ovarian cancer overview, including disease definition, epidemiology, discussion of unmet needs, and market potential
  • Current treatment options for ovarian cancer and ongoing controversies
  • Examination of the late-phase ovarian cancer pipeline, including drug profiles of late-stage agents
  • Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU


Ovarian cancer is the leading cause of death from gynecological malignancies in the Western world. This is because the majority of epithelial ovarian cancer patients present with advanced disease at diagnosis, where treatment has a palliative rather than curative intent.

While first-line platinum-based chemotherapy can result in high response rates of over 70-80%, the majority of patients will advanced epithelial ovarian cancer will eventually relapse with incurable disease. As such, there is a need for novel first-line therapies to improve survival rates.

R&D interest in ovarian cancer is high. There are currently 85 drugs in the pipeline, which is dominated by molecular targeted therapies (42%) and cytotoxic therapies (33%). Competition for the approval of the first molecular targeted therapy in ovarian cancer is fierce.

Reasons to Purchase

  • Estimate the number of treatable patients and identify unmet needs for future drug development opportunities
  • Understand the current treatment of the disease, as well as opportunities and threats in the ovarian cancer market
  • Analyze the current ovarian cancer pipeline and the potential of late-stage drugs

Table Of contents


Catalyst 1

Summary 1

About Datamonitor healthcare 2

About the Oncology pharmaceutical analysis team 2

Executive Summary 3

Scope of the analysis 3

Datamonitor insight into the ovarian cancer market 3

Related reports 4

Upcoming reports 4

Table of Contents 5

Patient Potential 6

Key findings 6

Definition 6

Epithelial tumors 7

The vast majority of ovarian cancers are epithelial in origin 7

The majority of epithelial ovarian cancers are sporadic in nature 8

Germ cell tumors 8

Sex cord-stromal tumors 8

A successful screening test for ovarian cancer has not been developed 8

Ovarian cancer is a surgically staged malignancy 9

Epidemiology 12

The incidence of ovarian cancer in the seven major markets is forecast to reach nearly 63,000 cases by 2019 12

The highest ovarian cancer rates prevail in Northern European countries 14

Current treatment options 15

Most early-stage patients are treated with surgery and chemotherapy 15

Surgery has a central role in the management of advanced disease 16

First-line platinum-based chemotherapy is the standard of care for advanced disease 17

The use of intraperitoneal chemotherapy remains controversial 20

Maintenance therapy has not been shown to improve overall survival 21

The treatment of recurrent disease is rarely curative and depends on patients’ platinum sensitivity 22

Platinum-based combination chemotherapy is recommended for platinum-sensitive recurrent disease 23

A number of single agents can be used in the treatment of platinum-resistant recurrent disease 25

Unmet need 25

More effective agents are required for the treatment of advanced disease 25

An effective screening test could significantly improve patient survival 26

R&D efforts should be directed towards molecular targeted therapies 26

Less invasive surgical approaches should be explored for early-stage patients 27

Market potential 28

Key findings 28

Current market overview 28

Opportunities and threats 29

Opportunities 29

Significant unmet need remains in the treatment of advanced disease 29

There is increased interest in the development of molecular targeted therapies 30

There is a large patient base in ovarian cancer, and a high commercial attractiveness 30

Threats 30

The development of an effective screening modality could decrease the patient base 30

Pipeline Analysis 31

Key findings 31

Ovarian cancer pipeline overview 31

Ovarian cancer late-phase pipeline 37

Avastin (bevacizumab; Genentech/Roche/Chugai) 37

Drug profile 37

Development overview 38

Product positioning 41

SWOT analysis 42

Karenitecin (cositecan; BNP-1350; BioNumerik) 43

Drug profile 43

Development overview 44

Product positioning 46

SWOT analysis 47

Opaxio (paclitaxel poliglumex; Cell Therapeutics/Novartis) 47

Drug profile 48

Development overview 48

Product positioning 49

SWOT analysis 50

Paclical (micellar paclitaxel formulation; Oasmia) 52

Drug profile 52

Development overview 52

Product positioning 53

SWOT analysis 54

Tarceva (erlotinib; Genentech/Roche/Chugai/OSI) 55

Drug profile 55

Development overview 55

Product positioning 58

SWOT analysis 59

Vargatef (intedanib; BIBF-1120; Boehringer Ingelheim) 60

Drug profile 60

Development overview 61

Product positioning 62

SWOT analysis 63

Votrient (pazopanib; GlaxoSmithKline) 63

Drug profile 63

Development overview 64

Product positioning 67

SWOT analysis 68

Farletuzumab (MORAb-003; Morphotek/Eisai) 69

Drug profile 69

Development overview 70

Product positioning 73

SWOT analysis 74

Abagovomab (Menarini/Cell Control Biomedical) 74

Drug profile 74

Development overview 75

Product positioning 77

SWOT analysis 77

Bibliography 79

Journals 79

Websites 84

Datamonitor reports 86


Contributing experts 87

Report methodology 87

About Datamonitor 87

About Datamonitor Healthcare 87

About the Oncology analysis team 88

Disclaimer 90

Browse complete Stakeholder Opinions: Ovarian Cancer – Approaching the era of molecular targeted therapy Report

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports RSS

Browse all Latest Report

Related Reports:

Stakeholder Opinions: Gastric Cancer – Targeted therapies compete for first-to-market status

Commercial Insight: Molecular Targeted Cancer Therapies

Pipeline Insight: Prostate Cancer Molecular targeted therapies will fulfill unmet needs in castration-resistant disease

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004